Purpose. The surface contamination levels of 5 commonly used hazardous drugs in hospital pharmacies are summarized, identifying practice patterns associated with contamination.
H azardous drugs are known to be harmful to both healthy and cancerous cells. The mechanism of action of hazardous drugs involves interference with cellular synthesis, providing therapeutic benefits in patients but potential harm to healthy human cells. 1 The doses at which hazardous drugs provide therapeutic benefit have been well studied and are reflected in Food and Drug Administration-approved dosing of these agents. One element that is often overlooked, however, is the health and safety of the health care workers that prepare and administer hazardous drugs, most notably pharmacy and nursing personnel.
The recognition of occupational exposure to hazardous drugs can be traced back to the late 1970s when biologic monitoring revealed contamination exposure in nurses who handled hazardous medications. 2 Since then, many studies have documented occupational hazardous drug exposures and the resulting adverse effects, which include mutagenicity and reproductive effects. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] In 2004, the National Institute for Occupational Safety and Health (NIOSH) released an alert statement for preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. This report specifically detailed that working with or near hazardous drugs in a health care setting can lead to adverse effects such as skin rashes, infertility, miscarriage, birth defects, and possibly leukemia or other cancers. 15 After recognizing this contamination and the health risks associated with occupational exposure, the health care community worked towards implementing various measures to minimize exposure to hazardous drugs. In this effort, groups including NIOSH, the American Society of Health-System Pharmacists, and the International Society of Oncology Pharmacy Practitioners have published guidelines addressing the safe handling of hazardous drugs. [15] [16] [17] Interventions included in these guidelines were implementing vertical laminar airflow biological safety cabinets, providing personal protective equipment to workers, introducing closed-system transfer devices (CSTDs) for hazardous drug preparation and administration, and providing routine medical surveillance measures for staff. While each of these methods has reduced occupational exposure to hazardous drugs to some extent, surface contamination is still a prevalent concern in hospital pharmacies and nursing units, [18] [19] [20] [21] [22] [23] especially in regard to surface contamination on the outside of hazardous drug vials. [24] [25] [26] [27] [28] The new United States Pharmacopeia (USP) chapter 800 and provides workplace standards to protect personnel when handling hazardous drugs. 29 USP chapter 800 recommends that environmental wipe sampling for hazardous drug surface residue be performed every 6 months, or more often as needed, to evaluate for the presence of contamination. While USP chapter 800 gives recommendations for frequency of contamination testing, it does not provide any guidance on how extensive the testing should be, including how many locations or how many drugs should be tested. Connor and colleagues 30 published a review on the available literature to date on hazardous drug wipe sampling and provided recommendations for wipe sampling in health care settings. In their review they acknowledged the lack of guidance on acceptable levels of contamination but concluded that monitoring surface contamination levels still plays a key role in evaluating current hazardous drug compounding practices and identifying opportunities for improvement. Routine monitoring of contamination sites is crucial in allowing institutions to be proactive in minimizing hazardous drug contamination. While a site does not want to undermonitor and risk missing evidence of contamination, it also does not want to overmonitor and waste resources.
Several studies have reported contamination exposures with and without the use of a CSTD [31] [32] [33] [34] ; however, only 1 study to our knowledge has reported additional characteristics of hazardous drug surface contamination including the locations associated with higher contamination levels and the rate of contamination at first wipe event compared to subsequent wipe event.
The Monitoring-Effect Study of Wipe Sampling in Pharmacies included both hospital and outpatient pharmacies in Germany and required professionals to visit and perform wipe sampling at each site. Our study is the first study of its kind to report contamination data that reflects individuals that conduct their own wiping and monitoring. 35 The objective of this study is to summarize the surface contamination levels of 5 commonly used hazardous drugs (docetaxel, paclitaxel, cyclophosphamide, ifosfamide, and fluorouracil) in hospital pharmacies. This study also summarizes the locations that correspond with the highest contamination levels, the rate of contamination at first wipe event compared to subsequent wipe events, and the rate of contamination at institutions that use CTSDs compared to those that do not use CSTDs.
Methods
The hazardous drug surface exposure analysis was performed using ChemoGLO (Chapel Hill, NC) hazardous drug contamination wipe kits, which analyze and quantify the amount of surface contaminants of hazardous drugs including docetaxel, methotrexate, cyclophosphamide, ifosfamide, fluorouracil, paclitaxel, and platinum analogs (e.g., cisplatin, carboplatin, and oxaliplatin). Detailed methods for wipe sampling and analyses of wipe samples have been published previously. 36 This study retrospectively evaluated nearly 6 years (from August 2009 through June 2015) of wipe data collected in 338 pharmacies from separate health care
KEY POINTS
• Routine hazardous drug contamination testing allows personnel to identify areas associated with contamination and advocate for contamination reduction, protecting workers against occupational exposures.
• Hazardous drug contamination testing should include locations both directly and indirectly associated with hazardous drug compounding and should test for multiple hazardous drugs used most commonly.
• For each wipe event, the institution filled out a data collection sheet, indicating the number of drugs and locations to be tested. The majority of institutions chose to test for 5 different drugs at 6 different locations. The data collection sheet also gathered site-specific practices, such as the time of day the site performed the wipe testing, whether the area was cleaned prior to testing, and the use of CSTDs. We included all wipe results in our analysis, even if the area was cleaned prior to testing. This was done to maintain the representation of how contamination testing is being performed in real-world scenarios.
The highest contamination rates for each drug among the locations tested were used to summarize the surface contamination. All reported locations were categorized into 6 different groupings: airfoil, floor below a biological safety cabinet (BSC), BSC surfaces, pharmacy surfaces (not including BSC), floor of the pharmacy (not directly under BSC), and miscellaneous items (including phones, keyboards, or chemotherapy transportation bins in the pharmacy). The airfoil, floor below BSC, and BSC surfaces were considered to be locations at or near the site of hazardous drug compounding. The remaining locations, pharmacy surfaces (not including BSC), floor of the pharmacy (not directly under BSC), and miscellaneous items were considered to be locations not located near hazardous drug compounding.
Contamination results were categorized into either first wipe event or subsequent wipe events. The first wipe event was defined as the first time in which an institution ordered and performed a wipe test. Subsequent wipe events were defined as any wipe event that occurred at the same institution more than 4 weeks after a previous wipe event (separate wipe studies are normally performed every 1, 3, or 6 months).
The contamination level for each drug at each location was defined as nondetectable: ≤10 ng/ft 2 ). Factors evaluated included the locations corresponding to highest contamination levels for each drug at each site, rate of contamination levels at first wipe event compared to subsequent wipe events, and rate of contamination at institutions that reported use of a CSTD compared to those who did not use a CSTD.
The Cochran-Armitage trend test was performed to evaluate the association between overall contamination at subsequent wipe events compared to first wipe event and the association between overall contamination at institutions that used CSTDs compared to institutions that did not use CSTDs.
Results
This study evaluated 799 total wipe events, which consisted of 5,842 individual wipe samples. The results included 338 unique health care institutions that completed at least 1 wipe event, with 39.64% of these unique institutions completing a subsequent wipe event. The health care institutions that completed at least 1 wipe event represent diverse geographical regions within the United States (20.40% Southwestern region; 16.65% Southeastern region; 13.14% Northeastern region; 29.91% Midwestern region; 18.65% Western region; and 1.25% were outside of the United States). Participating sites reported the time of day the wipe event was performed (29.66% reported at the start of the work day; 38.17% reported in the middle of the work day; 20.28% reported at the end of the work day; and 11.89% did not include information). Sites also reported whether the surface tested was cleaned prior to wipe sampling (13.52% reported cleaning prior to wipe sampling; 75.09% reported no cleaning prior to wipe sampling; and 11.39% did not include information). Participating sites were also asked to report whether or not CSTDs were used in hazardous drug preparation (75.47% reported using CSTDs; 17.40% reported not using CSTDs; and 7.13% did not include information).
Each institution self-reported on the wipe kit data collection sheet the location in which each wipe was performed. The locations corresponding with the highest detected contamination level for each drug per wipe event are summarized in Table 1 The contamination results for each drug from each wipe event were analyzed and categorized into either first wipe event or subsequent wipe events. The rate of contamination for each drug at first and subsequent wipe events is summarized in Table 2 . The rate of wipe results with high, medium, or low contamination was less on subsequent wipe events compared to first wipe event, with the exception of the ifosfamide high contamination results. There was a lower rate of high contamination for ifosfamide on first wipe event compared to subsequent wipe events (5.84% and 6.61%, respectively). The rate of wipe results with nondetectable contamination was higher for each drug on subsequent wipe events compared to first wipe event. The overall rate of contamination levels (compiling high, medium, and low levels) for all drugs was lower at subsequent wipe events compared with first wipe event (Z = −8.47; p < 0.0001).
Based on institutional practices indicated on the wipe kit data collection sheet, all wipe results for each of the 5 drugs tested were stratified into either CSTD users or CSTD nonusers. For CSTD users, the rate of various contamination levels for each drug was quantified. The same was done for CSTD nonusers and the rate of contamination was compared between CSTD users and CSTD nonusers. The results are summarized in Table  3 . There was a higher rate of high, medium, or low contamination results in the CSTD nonusers' category compared to CSTD users, with the exception of fluorouracil low contamination results. The fluorouracil contamination results had equal rate of low contamination results between CSTD users and nonusers (12.88%). There was a higher rate of nondetectable contamination results in the CSTD users' category compared to CSTD nonusers. However, as depicted in the results, there were still low, medium, and high levels of exposures of all drugs, even with the use of a CSTD (14.37%, 12.84%, and 6.30%, respectively). The overall rate of contamination levels (compiling high, medium, and low levels) for all drugs was higher for CSTD nonusers compared to CSTD users (Z = 8.73; p < 0.0001).
Discussion
The data summaries in this study showed that there is a high variability in the surface exposures of hazardous drugs in pharmacies. The majority of the highest contamination results corresponded to locations where hazardous drugs were prepared. A higher rate of contamination was identified at first wipe event compared to subsequent wipe events (p < 0.0001). Additionally, a higher rate of high, medium, and low contamination levels was detected at institutions that did not use CSTDs compared to institutions that did use these devices (p < 0.0001).
The contamination results stratified by location are consistent with previous contamination results published in the literature showing that surface contamination can be found at the site of compounding as well as other locations throughout the pharmacy. [18] [19] [20] 35 While the majority of highest contamination results in this study corresponded to locations involved in the preparation of hazardous drugs, it is important to note that the choice of locations tested was at the discretion of the institution, and that an institution may have tested locations involved in hazardous drug preparation more frequently. It is also important to note that contamination still exists in other areas of the pharmacy not directly involved in compounding (i.e., floors not beneath the BSC, pharmacist checking counters, and phones or keyboards). The awareness that contamination exposures are occurring at locations at or near the preparation of hazardous drugs suggests that additional measures should be taken at these sites to decrease contamination during the preparation process, but efforts should not exclude other areas throughout the pharmacy.
The difference in rates of contamination between results at first wipe event and subsequent wipe events suggests that monitoring is beneficial in recognizing and correcting practices, which can help prevent future surface exposures. This finding is consistent with previously published literature by Kiffmeyer and colleagues, 35 which found that repeated contamination monitoring had a stronger effect on contamination levels compared to a one-time contamination measurement. Contamination was not completely eliminated at subsequent wipe events, suggesting that continued monitoring is required with the inclusion of additional or different strategies to reduce exposure. Hazardous drug contamination wipe studies can be performed before and after a change in compounding practice or a change in protective measures in a hospital, which allows an institution to quantify the impact the intervention made in reducing contamination levels. The ultimate goal is nondetectable levels of contamination in each wipe throughout the pharmacy and institution. Thus, hospitals need to continue monitoring surface exposures to evaluate if they are maintaining best practices in order to keep contamination levels at a minimum. The practice of repeated surface contamination testing is consistent with the recommendations in USP chapter 800 that testing should be performed routinely (at baseline and then at least every 6 months, or more frequently if needed) to confirm containment of the contamination. 29 We observed that only 39.64% of institutions in our study participated in subsequent wipe events. This is important to note, and it raises concern for why 60% of institutions are not following USP chapter 800 recommendations for routine contamination monitoring. Due to the self-reporting nature of our data, we were unable to compare the change in contamination levels at institutions that did participate in subsequent wipe events. We recommend performing further analysis in the future to determine the reasons institutions do not participate in subsequent wipe sampling and identify if the rate of subsequent wipe sampling changes when USP chapter 800 is enforced in December 2019.
While USP chapter 800 does not detail the locations or number of drugs that should be tested, the data presented here supports testing a variety of drugs and locations within the pharmacy (locations directly and nondirectly involved in hazardous drug preparation) for hazardous drugs that are compounded most often at that institution. The majority of institutions chose to test 6 different locations for the 5 most commonly used chemotherapies at their institution. Until further research suggests otherwise, the data from this study supports testing a minimum of 5 drugs at 6 different locations to get an accurate summary of overall contamination levels within a hospital pharmacy.
One method in decreasing hazardous drug exposure during preparation is the use of a CSTD. 23, [31] [32] [33] [34] The data from this study showed a lower rate of contamination at institutions that used CSTDs in the preparation process. It is important to note that low, medium, and high contamination levels still existed at institutions using CSTDs, suggesting that the use of a CSTD did not completely remove or prevent all exposures. The additional use of cleaning products in the preparation areas before and after the use of CSTDs addresses both of these issues. 36 The lower rate of contamination at institutions that reported use of CSTDs supports the USP chapter 800 recommendation to use CSTDs as an adjunctive protection method in preparation and administration of hazardous drugs. 29 While the desired goal is to have nondetectable surface contamination, it should be evident that this is not achieved in all situations and there is a high variability in surface exposures of hazardous drugs in pharmacies. Even ). e p-value comparing the overall results for high, medium, low, and nondetectable contamination levels at first and subsequent results is p < 0.0001 for all groups.
AM J HEALTH-SYST PHARM | VOLUME 76 | NUMBER 9 | MAY 1, 2019 at institutions where best practices are implemented, the data in this study show that surface contamination was detectable in variable and unpredictable levels. The reasons for this are unclear but may include spills or breaking of a vial, not implementing all best practices, inconsistent use of safety practices and personal protective equipment, variability in the appropriate use of CSTDs, the ability of the CSTD to be truly closed, and external contamination of hazardous drug vials from the manufacturer. [24] [25] [26] [27] [28] 37 So while nondetectable contamination is not always possible, routine contamination testing is useful in identifying areas of contamination and implementing changes to prevent future contamination. It is important to note that while contamination testing can identify current exposures, which then can stimulate actions that prevent future exposures, the only way to eliminate existing contamination is through proper deactivation, decontamination, cleaning, and disinfecting procedures outlined in USP chapter 800. 29 A limitation of this study was the exclusion of contamination results from nursing and drug administration areas. The 2004 NIOSH Alert detailed that occupational exposure to hazardous drugs can occur at many points in the medication use process from procurement of the drugs to administration of drugs to patients. 15 However, the focus of this study was on pharmacy practice patterns and the rate of exposures of hazardous drugs. Future research and studies in other areas, such as nursing and administration areas, are needed. In regard to pharmacy-specific practices, additional characteristics that should be evaluated in future studies include the volume of chemotherapy preparations at each institution daily, which CSTD was used, whether CSTDs were used in all preparations including fluorouracil pumps, the level of experience of staff compounding the hazardous drugs, and the cleaning processes within the pharmacies.
To date, this is the largest study evaluating pharmacy practices and characteristics associated with levels of hazardous drug surface contamination. The highest contamination results occurred at locations both directly and indirectly involved in hazardous drug compounding, suggesting drug exposures can travel throughout the pharmacy. A higher rate of contamination was identified at first wipe event compared to subsequent wipe events, suggesting that monitoring is beneficial in recognizing and correcting practices that lead to hazardous drug surface exposures, preventing future contamination from occurring. Contaminations were not completely eliminated at subsequent wipe events, suggesting that continued monitoring is required with the inclusion of additional or different strategies to reduce exposures. A higher rate of high, medium, and low contamination levels was detected at institutions that did not use a CSTD compared to institutions that did use these devices. However, the use of a CSTD did not completely prevent all exposures, further suggesting that multiple practices, such as combining a CSTD with a cleaning product, should be implemented in hazardous drug preparation areas to reduce and prevent exposures.
Conclusions
The majority of highest contamination levels corresponded to locations where hazardous drugs were prepared. While the rate of contamination was lower at subsequent wipe events and at institutions that used CSTDs, contamination was not completely eliminated in either scenario.
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